Last reviewed · How we verify
CAPOX/SOX/FOLFOX
CAPOX/SOX/FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents.
CAPOX/SOX/FOLFOX are combination chemotherapy regimens that inhibit DNA synthesis and cell division through fluoropyrimidine and platinum-based cytotoxic agents. Used for Colorectal cancer (metastatic and adjuvant settings), Gastric cancer, Pancreatic cancer.
At a glance
| Generic name | CAPOX/SOX/FOLFOX |
|---|---|
| Sponsor | Fujian Cancer Hospital |
| Drug class | Combination chemotherapy regimen (fluoropyrimidine + platinum agent) |
| Target | Thymidylate synthase (5-FU); DNA (oxaliplatin cross-linking) |
| Modality | Small molecule |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
These regimens combine 5-fluorouracil (or capecitabine/S-1 oral prodrugs) with oxaliplatin, a third-generation platinum compound. The fluoropyrimidines inhibit thymidylate synthase and incorporate into DNA/RNA, while oxaliplatin forms DNA cross-links, leading to apoptosis in rapidly dividing cancer cells. The combination provides synergistic cytotoxic activity against solid tumors.
Approved indications
- Colorectal cancer (metastatic and adjuvant settings)
- Gastric cancer
- Pancreatic cancer
- Esophageal cancer
Common side effects
- Neutropenia
- Nausea and vomiting
- Diarrhea
- Peripheral neuropathy
- Anemia
- Mucositis
- Hand-foot syndrome (capecitabine-based)
Key clinical trials
- Timing of Minimally Invasive Local Treatment After First-Line Systemic Therapy in Oligometastatic Esophageal or Gastric Adenocarcinoma (PHASE2, PHASE3)
- Fruquintinib Combined With PD-1 Inhibitor as First-line Maintenance Therapy for Advanced Gastric Cancer (PHASE2)
- A Randomized Phase III Study Comparing POF With SOX/CAPOX/FOLFOX as a Postoperative Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAPOX/SOX/FOLFOX CI brief — competitive landscape report
- CAPOX/SOX/FOLFOX updates RSS · CI watch RSS
- Fujian Cancer Hospital portfolio CI